March 23, 2020

Governor Mark Gordon
State Capitol
200 West 24th St
Cheyenne, WY 82002

Dear Governor Gordon,

The 22 undersigned organizations, representing thousands of patients and consumers across Wyoming who face serious, acute, and chronic health conditions, urge lawmakers to act decisively to slow the spread of the COVID-19 virus, particularly among vulnerable populations, and begin to prepare for the future. People with pre-existing conditions are at increased risk of infection and adverse health outcomes from COVID-19.

Specifically, we ask Wyoming to take swift action to remove barriers to COVID-19 testing and treatment, promote continuity of care for Americans with serious health conditions, and waive rules that require in-person interactions that promote community spread of COVID-19. We also urge the executive branch to enact emergency measures that allow for increased funding for Medicaid and public health services to immediately respond to the current crisis, including taking advantage of newly available federal funding, and consider additional critical measures that will help protect people with pre-existing conditions, given their greater risk of adverse health outcomes during this pandemic.
Medicaid
Medicaid’s coverage for low-income individuals and families is more important now than ever. We call on both the executive and legislative branch to take action to ensure Medicaid is available and affordable to all state residents, including those who are currently uninsured. Due to the enactment of H.R. 6201, the federal matching assistance percentage (FMAP) has been increased, which will reduce the state’s share of its Medicaid expenditures by 6.2%. In light of this action, our organizations urge Wyoming to take the following steps.

Promote access to coverage
Streamlining and removing barriers to Medicaid eligibility is an immediate step states can take to expand access to health insurance coverage that includes testing and treatment. We strongly encourage Wyoming to quickly utilize regulatory flexibilities allowed under section 1135 waivers, Appendix K of the 1915(c) Home and Community-Based Services (HCBS) Waivers, and state plan amendments (SPA) to expand access to eligible individuals. This includes: adopting additional eligibility groups; increasing effective income standards; expanding hospital presumptive eligibility groups; removal of cost-sharing; and waiving prior authorization requirements.

Free testing regardless of diagnosis
It is critical that anyone who needs diagnostic testing related to COVID-19 is able to receive testing at no cost. In this emergency, we cannot allow affordability of testing and associated care to become a barrier that prevents people from taking appropriate action if they show symptoms. We urge you to immediately begin working on a SPA to extend free coverage of COVID-19 diagnosis and testing to newly eligible uninsured individuals. As authorized in H.R. 6201, this option is now available to states and can be covered 100% with federal funding.

Access to COVID-19 treatment and vaccine with no cost-sharing
Further, we recognize that after diagnosis, patients may be liable for substantial costs related to their quarantine and treatment. Recent media reports indicate that consumers diagnosed with COVID-19 may face extreme costs because of the nature of their treatment and quarantine. Fear of encountering high costs could keep those who have been exposed or infected with the COVID-19 virus from seeking the care they need – potentially perpetuating the spread of this deadly virus.

The increased FMAP in H.R. 6201 includes that states must offer treatment, including vaccine and specialized care, with no cost sharing. We urge you to quickly accept the increased funds and implement this provision. Additionally, when a vaccine is approved, all Medicaid enrollees should have access to it with no cost-sharing, not just those required by federal law.

Maximize the ability of patients to access care via telemedicine
Telemedicine has the potential to offer individuals and families access to health care services from the safety of their own home. The state should expand access to and availability of, telemedicine services during the COVID-19 pandemic to ensure that patients with pre-existing conditions can easily access health care expertise while simultaneously practicing safe social distancing—allowing patients to avoid being exposed to COVID-19 in provider waiting rooms, exam rooms, and during associated travel. Wyoming should ensure that telemedicine services are covered at no higher cost-sharing than in-person visits, and that bureaucratic hurdles do not prevent a sufficient number of health care providers from participating. The Centers for Medicare and Medicaid Services (CMS) recently released standards for Medicare coverage of telemedicine during this emergency, which waives telehealth reimbursement.
restrictions so that providers can more easily communicate with patients via easily accessible
technology in more situations and settings. Additionally, CMS released guidance on how states can use
existing authorities and flexibilities of the Medicaid program to make services via telemedicine available
without federal approval. We encourage the state to utilize these flexibilities – including, at a minimum,
the coverage now available through Medicare – to offer robust coverage to all Medicaid enrollees.

**Ensure access to sufficient supplies of essential medications and medical products**

Insurance plan restrictions on how often a patient can refill prescription or purchase essential medical
supplies may put a person at risk. Limitations on refills can require frequent trips to a physical pharmacy
location, needlessly putting patients at risk of COVID-19 exposure while attempting to pick up their
supplies. Medicaid should immediately remove any restrictions, including cost-sharing, that prevent
patients from following the recommendations of the CDC to secure an appropriate amount of backup
supplies of essential medications and medical products.

**Free testing regardless of diagnosis**

Just as in Medicaid, access to testing without cost barriers is critical in the commercial market. Many
Americans understand that cost-sharing associated with emergency department (ED) visits, urgent care
visits, and lab testing is often quite costly which can create barriers to timely care. Although the federal
government has attempted to address cost barriers across several populations, we are concerned that
this approach has led to confusion about how cost-sharing will vary across various insurance types, and
urge the state to step in to ensure all state-regulated plans offer free testing. We ask that you take steps
to require all plans to cover testing before the deductible is met, with no cost-sharing. This should
include testing when deemed necessary by a medical professional, whether the patient is later
diagnosed with COVID-19 or not. Due to the lack of consistently available testing to date, this must also
include coverage of out-of-network laboratory testing.

**Accessible and affordable COVID-19 treatment and vaccine**

We have serious concerns about the financial risk consumers may face if they are diagnosed. Recent
analysis shows the cost of an inpatient admission could be over $20,000. We call on the state to
require plans provide affordable coverage for these necessary treatments, including:

- First dollar coverage of treatment before the deductible is met, including off formulary
  medications and out-of-network providers when necessary. As treatment protocols for COVID-
  19 patients evolve, formularies may not evolve as fast, it is critical that patients be held
  harmless in this process.
- Coverage of telemedicine services with in-network cost sharing to ensure patients can access
treatment without being exposed to COVID-19 in an in-person setting.
- When a vaccine becomes available, coverage must be provided with no cost-sharing.

**Ensure access to sufficient supplies of essential medications and medical products**

As with Medicaid, we urge the state to ensure that plan restrictions on when a patient can obtain a
prescription refill or purchase essential medical supplies be suspended at this time. It is critically
important that patients be able to access life-sustaining medications and products without putting
themselves at risk with frequent trips to the pharmacy. Plans must allow patients to follow CDC
recommendation to secure an appropriate amount of backup supplies of essential medications and
medical products.

**Protect patients from surprise bills**
Lastly, as we look to a future of economic uncertainty, protecting consumers from medical debt is of critical importance. Even in states that have taken steps towards eliminating surprise medical bills, there may be more that can be done. We urge you to prohibit surprise bills from out-of-network providers for treatment for COVID-19. This financial protection should include all providers, settings, and insurance types to ensure that everyone who needs testing and treatment is able to receive timely and affordable care. Fear of surprise bills should not keep patients and consumers away from care during this critical time.

We thank you for your efforts thus far to protect vulnerable patients and stand at the ready to work with you going forward. If you have questions or would like to discuss further, please contact Brittany Duffy-Goche, State Government Relations Manager, National Psoriasis Foundation at bduffy-goche@psoriasis.org if you have any questions.

Sincerely,

ALS Association  Hemophilia Federation of America
American Cancer Society Cancer Action  Leukemia & Lymphoma Society
Network  Mended Hearts & Mended Little Hearts
American Diabetes Association  Muscular Dystrophy Association
American Kidney Fund  National Eczema Association
American Liver Foundation  National Multiple Sclerosis Society
American Lung Association  National Organization for Rare Disorders
Arthritis Foundation  National Patient Advocate Foundation
COPD Foundation  National Psoriasis Foundation
Crohn’s & Colitis Foundation  Pulmonary Hypertension Association
Cystic Fibrosis Foundation  Susan G. Komen
Epilepsy Foundation

Cc: Commissioner Jeff Rude, Director Michael Ceballos, Senate President Perkins, Speaker Harshman

\(^{iii}\) https://www.cms.gov/newsroom/fact-sheets/medicare-telemedicine-health-care-provider-fact-sheet